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ABSTRACT
Preeclampsia (PE) is responsible for about 20% of the 13 million preterm births each year
worldwide, including 100,000 cases annually in the United States. Despite being a leading cause
of maternal and perinatal morbidity, the mechanisms of pathogenesis are still largely unknown.
PE is progesterone deficient state characterized by hypertension, chronic immune activation,
endothelial dysfunction and severe forms can lead to seizures. Treatment of seizures includes the
administration of magnesium sulfate (MgSO4) though not all PE patients are responsive, and it
does not decrease PE-associated hypertension. To resolve these conditions, PE patients are
delivered early thereby making PE the leading cause for fetal mortality and morbidity
worldwide. Hypothesizing that the reduced progesterone levels accounted for the onset of
hypertension in PE, the effects of both 17-hydroxyprogesterone caproate (17-OHPC) and
Progesterone Induced Blocking Factor (PIBF) were studied in hypertensive pregnant rat models
of PE. Following the intervention, blood pressure and endothelin-1 were reduced while nitric
oxide was elevated.
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INTRODUCTION
Preeclampsia (PE) is a multifactorial hypertensive disease that affects and complicates up
to 8% of pregnancies in the United States and 12% in Mississippi and is responsible for one-fifth
of all the preterm births in the United States annually5,7.
While PE results in high levels of maternal and perinatal morbidity, the only treatment
currently available is preterm delivery16. To allow for the development of mechanism-based
therapies to better manage patients with PE, efforts to identify the key components in the
pathogenesis of PE at the molecular level are currently underway. Findings from these prior
studies have discovered that PE is associated by decreased levels of progesterone, new onset
hypertension, chronic inflammation, mitochondrial dysfunction, and endothelial dysfunction2
(Figure 1). These PE-associated changes are typically diagnosed near the 20th week of pregnancy
to third trimester during pregnancy.
During the third trimester of a normal pregnancy, progesterone levels are measured to be
about 34 ng/mL9. In pregnant women with PE, this increase is not observed (15 ng/mL; Figure
2). A key signaling molecule during pregnancy, progesterone has the potential to impact a
number of physiological processes in pregnant women. As part of regulating the progesteronedependent pathways, the body releases factors like Progesterone Induced Blocking Factor (PIBF)
which helps to control proinflammatory mechanisms that occur early in gestation. PIBF then
goes on to stimulate Interleukin 4 (IL-4) and therefore increase Th2 cytokines. IL-4 and Th2
cytokines are thought to promote a more tolerant, anti-inflammatory environment that protects
the fetus. PIBF in women without PE, also helps to crease cytolytic natural killer (NK) cells as
well as Th1 cytokines (Figure 3, 4). Thus if, progesterone is decreased then likewise, so is PIBF
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and these inflammatory processes are not appropriately regulated. 17-ortho hydroxyprogesterone
(17-OHP) is a progesterone that is mainly produced by the adrenal glands, gonads, and ovaries
(Figure 5). Clinically, 17-orthohydroxyprogesterone caproate (17-OHPC) is a synthetic
progesterone that is currently utilized for treating preterm labor in pregnant women without PE.
However, due to the lack of clinical data, it is not yet used as a treatment for PE6, 13-14.
Mitochondrial oxidative stress refers to the production of more than normal amounts of
reactive oxygen species (ROS) from the mitochondria. Circulating factors such as inflammatory
cytokines and cells induce mitochondrial dysfunction in a preeclamptic placenta which can lead
to a high instance of mitochondrial DNA damage as well as impaired function of the
mitochondria in the electron transport chain2.
Endothelial dysfunction is a condition in which the endothelial layer (the inner lining) of
the small arteries fails to perform all of its important functions normally. It is characterized by
increased levels of sFlt-1 and ET-1, as well as a decrease in levels of nitric oxide (NO). sFlt-1 is
a soluble vascular endothelial growth receptor (VEGFR1). VEGF is important in maintaining the
vascular endothelium but is antagonized by sFlt-1 during PE (Figure 6). Endothelin-1 is a potent
vasoconstrictor while nitric oxide is a vasodilator11. This results in a strong correlation leading to
increased levels of ET-1 and decreased levels of NO. This imbalance leads to chronic
vasoconstriction.
During early stages of pregnancy complicated by preterm labor, but not preeclampsia, 17OHPC is given to patients as early as 20 weeks13,14. 17-OHPC is delivered to these patients
weekly in order to prolong labor and has increased time to delivery, yet there is no
administration of 17-OHPC to patients afflicted with severe preterm preeclampsia.
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Figure 1: Factors Contributing to Preeclampsia18
There are several factors that contribute to placental dysfunction such as a genetic
component, Angiotensin II Type-1 Receptor Autoantibodies, Natural Killer cells,
oxidative stress, and various other factors. Placental dysfunction leads to an excess of
sFlt-1 and soluble endoglin (sEng) as well as increased growth restriction of the fetal
unit. The outcomes of this are hypertension, proteinuria, and various other complications.
This comprehensive figure illustrates the multifactorial components leading to
preeclampsia.
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Figure 2: Progesterone Levels in Normal Pregnancy Versus Preeclampsia9
The graph above demonstrates the levels of circulating progesterone in a normal
pregnancy versus during preeclampsia. In normal pregnancy, plasma progesterone levels
are around 34 ng/ml, whereas preeclamptic patients have significantly lower levels
(p<0.013) of about 14 ng/ml.

xi

Figure 3: PIBF Levels in Normal Pregnancy Versus Preeclampsia19
Progesterone Induced Blocking Factor (PIBF) in normal pregnancy increases to level
around 110 ng/ml in the 30-37-week period of gestation. During preterm labor, PIBF
concentration is significantly lower with its highest concentration being around 10 ng/ml
in the 20-29-week period.
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Figure 4: PIBF Diagram10
During pregnancy, progesterone activates Progesterone Induced Blocking Factor (PIBF),
which goes on to initiate a series of events. PIBF inhibits T-helper type 1 (Th1) cells,
lowering levels of interleukin-2 (IL-2), interleukin-12 (IL-12), and Tumor Necrosis
Factor alpha (TNF⍺). PIBF also inhibits Natural Killer (NK) cells. T-helper type 2 (Th2)
cells are activated which promotes interleukin-4 (IL-4), interleukin-6 (IL-6), and
interleukin-10 (IL-10). PIBF also activates B cells, or B lymphocytes, to help with
humoral immunity and the production of antibodies.
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Figure 5: Progesterone and 17-OHPC Structures
The structural formulas shown are natural progesterone produced in the body, 17-alphahydroxyprogesterone with is a natural progestin, and 17-hydroxyprogesterone caproate
which is a synthetic hormone.
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Figure 6: sFlt-1 and VEGF22
sFlt-1 is one of the main contributors to placental dysfunction. In a normal pregnancy,
Vascular Endothelial Growth Factor binds to its FLT1 receptor. This, in turn, promotes
angiogenesis, or the development of new blood vessels. During preeclampsia, an excess
of the soluble fms-like tyrosine kinase receptor binds VEGF, creating an antiangiogenetic
effect. This antiangiogenetic effect impairs relaxation of the blood vessels, leading to
endothelial dysfunction.
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METHODS
Inducing Hypertension via the sFlt-1 Model
The pregnant Sprague-Dawley rats used for this study were obtained from Harlan
Sprague Dawley in Indianapolis, Indiana (Figure 7A). The rats were kept in housing conditions
that consisted of a 23°C temperature room with access to food and water. Animals weighing
200-250g were randomly assigned to Normal Pregnant (NP; control) or NP + sFlt-1 groups. On
day 13 of gestation, the NP + sFlt-1 group rats were put under anesthesia in order to place the
sFlt-1 mini osmotic pump into the abdominal cavity to induce hypertension (Figure 7B). This
pump dosage was designated as 3.7 µm·kg-1·day-1 for 6 days, the 6 days representing days 13-19
of the animals’ gestation period. After the animals’ abdominal cavities were sutured, analgesics
were applied via subcutaneous injection of 5 mg/kg Carprofen once a day for 2 to 3 days. All
experimental procedures performed in this study were executed in accordance with the National
Institute of Health guidelines developed for the use and care of animals. All protocols were
approved by the Institutional Animal Care and Use Committee at the University of Mississippi
Medical Center. Surgical procedures were carried out under the appropriate anesthesia and
analgesics were give post-operatively as needed, under the supervision of the veterinary staff.
17-OHPC Administration
On day 15 and 18 of gestation, a group of NP + sFlt-1 treated rats were intraperitoneally
injected with 17-OHPC. The solution dosage administered was 0.5 cm3 solution of 3.32 mg/kg9.
The NP rat group were not treated with an injection of 17-OHPC because the previous studies
demonstrate no effect on blood pressure or other molecular factors in NP rats3 and is therefore
seen as an unnecessary procedure for the rat.
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PIBF Administration
On day 15 of gestation, a group of NP + sFlt-1 treated animals were intraperitoneally
injected with PIBF at a dosage of 2.0 µm/mL. This dosage was chosen from previous
experiments inducing hypertension with the Reduced Uterine Perfusion Pressure (RUPP) model.
These experiments showed that the appropriate in vivo dosage was 2.0 µm/mL in order to
decrease signs of preeclampsia in response to elevated sFlt-1 during pregnancy.
Mean Arterial Blood Pressure Measurement
On day 19 of gestation, the animals were placed under isoflurane anesthesia so carotid
arterial catheters could be inserted in order to measure blood pressure. The catheters were placed
into the carotid artery towards the back of the animal’s neck to be made available externally.
Blood pressure was then measured via a pressure transducer and recorded for 30 minutes after a
30-minute stabilization period. After measuring MAP, the animal’s tissues were harvested, blood
samples were collected, and pup and placenta weights were recorded.
Measuring Nitrate-Nitrite Levels
Plasma, obtained from the collected blood samples, was used in order to measure the
circulating nitrate-nitrite levels using the Nitrate/Nitrite Colorimetric Assay Kit from Cayman
Chemical (Ann Arbor, MI). Instructions that were induced were followed. The inter-assay
coefficient of variation is 3.4% while intra-assay coefficient of variation is 2.7%.2
Measuring Renal Cortex Preproendothelin-1 mRNA Levels
In order to measure renal cortex preproendothelin-1 (PPET-1) levels, real-time
polymerase chain reaction (RT-PCR) was used. The tissue samples from the kidney were stored
in a -80°C freezer. Tissue samples were homogenized, and RNA was extracted using the RNeasy
Protect Mini Kit from QIAGEN (Germantown, MD). A spectrophotometer was used in order
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determine the concentration and the quality of the RNA. RT-PCR was performed using iQ
SYBR Green Supermix and CFX96 Touch Real-Time PCR Detection System from Bio-Rad
Laboratories (Hercules, CA). The primer sequences for PPET that were used are
CTAGGTCTAAGCGATCCTTG forward and TCTTTGTCTGCTTGGC reverse.2
Measuring Mitochondrial Dysfunction
Placentas and renal samples taken from NP + sFlt-1 + PIBF animals were utilized in
order to establish the peroxide production of the mitochondria. These sample were put into a
mechanical homogenizer to lyse the cells. Next, the lysed cells are put through a centrifugation
process in order to extract the mitochondria. After this, sample are put through an Oxygraph-2K
to measure the amount of respiration or a fluorescence microplate reader in order to measure
mitochondrial peroxide. An amplex red assay was used where samples were placed on a 96 well
plate and put into a fluorescence microplate reader (Figure 8). The samples were incubated with
a respiration buffer, superoxide dismutase, horseradish peroxidase, and succinate. Amplex red
was added to start the reaction and the real-time production of peroxide was recorded. There
were also wells without amplex red in order to serve as a control.
Measuring Mitochondrial ROS23
In order to determine the amount of mitochondrial reactive oxygen species, MitoSOX red
dye was utilized. Serum obtained from the rats was used to determine mitochondrial ROS
production with human umbilical venous endothelial cells (HUVECs). Human umbilical venous
endothelial cells (HUVECs) were grown in HUVEC media and then cultured in a 6-well plate
and incubated overnight, in order to determine the vascular endothelial cell mitochondria
function. After incubation, these cells were washed and then incubated with MitoSOX red. Cells
were then washed with Dulbecco’s phosphate-buffered saline (DPBS) two times and incubated
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again in a serum free medium for 4 hours. After this, flow cytometry was utilized in order to
collect and analyze the cells. The basis of this assay is to determine if circulating factors mediate
endothelial mitochondrial dysfunction.
Statistical Analysis
All of the data are expressed as mean ± SEM. Comparisons of control with experimental
groups were analyzed by One-way ANOVA with Bonferroni multiple comparisons test as post
hoc analysis. A value of p < 0.05 was considered statistically significant.2
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B

A

Figure 7: Sprague-Dawley Rat and Incision Site
For this experiment, pregnant Sprague-Dawley rats were obtained from Harlan Sprague
Dawley in Indianapolis, Indiana (A). On the right, is a visual representation of the
incision made in the rat’s abdominal area in order to place the sFlt-1mini-osmotic pump
(B).

xx

Figure 8: Mitochondrial Respiration and HUVECs Experiment Process
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RESULTS
MAP was significantly increased in NP + sFlt-1 rats 117 ± 1 mmHg (n=13)
compared to the NP control rats 99 ± 2 mmHg (n=12, p < 0.05). After administering 17OHPC to these sFlt-1 treated rats, the MAP was significantly reduced to 102 ± 3 mmHg
(n=8) (Figure 9). 17-OHPC showed no changes in either placental or pup weight in
response to sFlt-1 or 17-OHPC during pregnancy (Figure 10). Recent study has shown
that 17-OHPC, when given to NP rats, shows no change to either placental or pup
weights3.
In the NP + sFlt-1 treated rats, the renal cortex PPET-1, which is a marker for ET1, showed a 3-fold increase compared to the NP animals. After administration of 17OHPC, PPET-1 levels were significantly reduced (n = 5-7/group, p < 0.05) (Figure 11).
Plasma nitrate-nitrite levels were 44 ± 9 µM in NP rats (n = 9), 20 ± 3 µM in NP
+ sFlt-1 (n = 7) and were increased to 42 ± 11 µM in 17-OHPC treated rats2 (n = 6)
(Figure 11).
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Figure 9: 17-OHPC Mean Arterial Pressure Graph2
Normal pregnant (NP) the mean arterial blood pressure (MAP) is 99 ± 2 mmHg (n=12).
When sFlt-1 is administered, the blood pressure is significantly increased to 117 ± 1
mmHg (n=13) compared to the NP group (p < 0.05). When the sFlt-1 group was treated
with 17-OHPC blood pressure was significantly reduced to 102 ± 3 mmHg (n=8) (p <
0.05).
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Figure 10: 17-OHPC Pup and Placenta Weight Graph2
Pup weight (left) did not differ between treatment groups: NP (n=12), NP + sFlt-1
(n=13), and NP + sFlt-1 + 17-OHPC (n=8). The graph of the right represents placenta
weight in grams. No significant difference was observed in placenta weight either (right
graph), although there is a slight upward trend between the sFlt-1 administered group
(n=13) to the 17-OHPC treated group (n=8).
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Figure 11: 17-OHPC Renal Cortex PPET-1 and Nitrate-Nitrite Graph2
Renal cortex preproendothelin-1 (PPET-1) levels were measured (left graph) and the sFlt1 administered group showed a significant increase in PPET-1 compared to the NP group.
When treated with 17-OHPC, PPET-1 levels were significantly lowered compared to the
sFlt-1 group (n = 5-7/group, p < 0.05). Circulating plasma nitrate-nitrite was measured
(right graph) with a level of 44 ± 9 µM in NP rats (n = 9), 20 ± 3 µM in NP + sFlt-1 (n =
7) and were increased to 42 ± 11 µM in 17-OHPC treated rats (n = 6).
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Mean arterial pressure (MAP) was increased in s-Flt-1 rats to 112 ± 2 mmHg (n = 9)
compared to control NP rats 98 ± 2 mmHg (n = 10, p < 0.05). Administration of PIBF reduced
MAP to 100 ± 1 mmHg in the presence of s-Flt-1 (n = 9, p < 0.05) (Figure 12). There was also
no change to pup weight between the NP, sFlt-1 treated, and PIBF treated animals (Figure 13).
Body weights were NP rats (317 ± 9.32 grams), s-Flt-1 rats (322 ± 8.07 grams), and s-Flt-1 rats
administered with PIBF (303 ± 6 grams).
PIBF was shown to reduce PPET-1 in response to elevated sFlt-1 during pregnancy,
which was done by real-time PCR. In both the placenta and the renal cortex, there was an
increase of endothelin-1 levels in the sFlt-1 treated rats compared to the NP rats. When treated
with PIBF, these rats had a significant decrease in levels of endothelin-1 compared to the sFlt-1
treated rats (Figure 14).
The nitrate-nitrite levels in the sFlt-1 treated rats were significantly lower than the NP
rats, but there was not a significant difference in the nitric oxide levels of the PIBF treated rats
(Figure 15).
Placental mitochondrial state 3 respiration decreased in NP + s-Flt-1 infused rats (n = 3)
(206 ± 67 pmol of O2/sec/mg, n = 4) compared to NP controls (n = 3) (268 ± 24 pmol of
O2/sec/mg). State 3 placental respiration in NP + sFlt-1 rats administered PIBF (n=5) (309 ± 153
pmol of O2/sec/mg) was elevated compared to NP + sFlt-1 rats. Uncoupled respiration also
decreased in NP + s-Flt-1 infused rats (n=3) (87 ± 42 pmol of O2/sec/mg, n=4) compared to NP
controls (n=3) (164 ± 21 pmol of O2/sec/mg, n=3) and NP + sFlt-1 rats administered PIBF (n=5)
(199 ± 93 pmol of O2/sec/mg, n=5) (Figure 16).
No effect was shown on renal mitochondrial reactive oxygen species and respiration with
PIBF treated rats (Figure 17).
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Figure 12: PIBF Mean Arterial Pressure Graph
Mean arterial pressure (MAP) for the PIBF treated rats. The sFlt-1 group showed
significant increase in blood pressure at to 112 ± 2 mmHg (n = 9) compared to the NP
group 98 ± 2 mmHg (n = 10, p < 0.05). The PIBF treated group indicated a significantly
lower MAP compared to the sFlt-1 group at 100 ± 1 mmHg (n = 9, p < 0.05).
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Figure 13: PIBF Pup Weight Graph
There was no difference in pup weight from the normal pregnant, sFlt-1 administered,
and PIBF treated groups.
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Figure 14: PIBF Placenta and Renal Cortex PPET-1 Graph
Placenta PPET-1 was measured in the graph to the right. In the sFlt-1 administered group
significantly high levels of PPET-1 were seen as compared to the normal pregnant group. When
treated with PIBF, PPET-1 levels were decreased compared to the sFlt-1 group. On the left
graph, renal cortex PPET-1 levels were measured. When the rats were given sFlt-1 the PPET-1
levels were increased significantly from the NP group. When treated with PIBF, the levels of
PPET-1 declined.
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Figure 15: PIBF Circulating Nitrate-Nitrite Graph
A significant decrease was seen in circulating nitrate-nitrite in the sFlt-1 group compared to the
normal pregnant group. When looking at the PIBF treated group, no change was seen compared
to the sFlt-1 group.
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Figure 16: PIBF Placenta Mitochondria ROS and Respiration Graph
For placental mitochondria Reactive Oxygen Species (ROS; top graph), in the sFlt-1 group there
was an increase in ROS compared to the NP group. The PIBF treated group displayed a
significant decrease in ROS contrasted to the sFlt-1 group. No significant difference in placental
mitochondria respiration (bottom right/left graphs) was seen, although the data suggests that
respiration in State 3 could increase.
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Figure 17: PIBF Kidney Mitochondria ROS and Respiration Graph
PIBF was shown to have no effect on renal mitochondria reactive oxygen species or renal
mitochondria respiration.

xxxii

DISCUSSION
A crucial part of a healthy pregnancy is the production of the hormone progesterone and
therefore the activation of Progesterone Induced Blocking Factor (PIBF). With lower levels of
progesterone and PIBF in preeclamptic patients comes other risk factors that makes it difficult to
have a full-term pregnancy. A person with preeclampsia shows symptoms of chronic
inflammation, high blood pressure, mitochondrial dysfunction, and endothelial dysfunction. This
consistent rise in blood pressure increases the risk of stroke, liver or kidney rupture and other
organ damage for the mother, making it a necessity to deliver the baby early.
According to the data shown, infusing sFlt-1 into pregnant animals stimulates many
characteristics of preeclampsia. Because the only management option for preeclampsia is an
intravenous injection of magnesium sulfate, which does not treat these symptoms, it is essential
to find a treatment to increase vasodilatory factors and decrease vasoactive factors and thus
hypertension for the mother. The only treatment available is early delivery of the fetus.
In order to increase vasodilatory factors such as nitric oxide and decrease vasoactive
factors such as endothelin-1, 17-orthohydroxyprogesterone caproate, a synthetic progesterone,
was used to mimic the effects of natural progesterone. Moreover, we hypothesized that the
administration of Progesterone Induced Blocking Factor, a protein resulting from progesterone
activating the progesterone receptor, would improve circulating factors such as nitric oxide and
endothelin and therefore improve renal and placental mitochondrial function. Taken together,
these factors would decrease maternal mean arterial blood pressure thereby allowing the
pregnancy to continue.
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According to the data collected, this study demonstrates that 17-OHPC improves
hypertension, circulating nitrate-nitrite, and endothelin-1. In addition, PIBF, a product of
progesterone signaling, safely decreases levels of endothelin-1, blood pressure, and placental
mitochondrial reactive oxygen species. Thus, PIBF may be the mechanism whereby 17-OHPC
could be beneficial to add to the current management of preeclampsia.
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